Panbela Provides Business Update and Reports Q2 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Panbela Therapeutics, Inc. (PBLA) Misses Q2 EPS by $1.25
August 15, 2022 4:56 PM EDTPanbela Therapeutics, Inc. (NASDAQ: PBLA) reported Q2 EPS of ($1.51), $1.25 worse than the analyst estimate of ($0.26).
For earnings history and earnings-related data on Panbela Therapeutics, Inc. (PBLA) click here.
... More